315723
How Meaningful Use (MU) Stage 3 may impact one central cancer registry’s progress in MU Stage 2
PURPOSE: Assess how MU Stage 3 could impact cancer Stage 2 reporting criteria as well as factors that may determine whether a C/PO will continue with MU past Stage 2.
METHODS: We are participating in a national workgroup to determine the impact MU Stage 3 will have on cancer reporting and working with certified MU Stage 2 EHR vendors to analyze and assess changes to cancer reporting stemming from Stage 3 requirements. We are also assessing impact on the CCR of additional data storage needed for Stage 2 and Stage 3 EHR data and estimating staffing needs and storage costs.
RESULTS: We will present estimated staffing and storage needs and costs, based on current knowledge. Final MU Stage 3 rules will not be completed until 2015. The 2015 edition EHR Certification Criteria will include problems that need to be addressed from the 2014 edition, respond to stakeholder feedback and reference updated standards and implementation guides moving toward more interoperability.
DISCUSSION: Under MU Stage 2, Cancer Reporting was an option that providers could choose. Additional proposed requirements for MU Stage 3 could enhance cancer data to the point where social and behavioral factors may be used to determine cancer risk assessments. It is hoped that MU Stage 3 will require elements optional in Stage 2 but it is feared that some C/POs will drop or not select cancer reporting.
Learning Areas:
Communication and informaticsLearning Objectives:
Discuss the impact Meaningful Use Stage 3 may have on EHR reporting to a central cancer registry (CCR).
List the effects Stage 3 are likely to have on providers that report to the CCR.
Assess the steps a CCR will need to take during the delay of Stage 3 implementation to be ready when it is implemented.
Qualified on the content I am responsible for because: I am the director of the Missouri Cancer Registry and Research Center. I was the principal investigator on 4-year project to bring data from physician office electronic health records directly into the central cancer registry as part of Meaningful Use (MU) – Stage 2 Cancer Reporting. This led to participation in a national workgroup visioning MU -Stage 3.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.